Loading...
XJPX4571
Market cap61mUSD
Jan 17, Last price  
136.00JPY
1D
0.00%
1Q
-20.00%
Jan 2017
-84.70%
IPO
-42.94%
Name

NanoCarrier Co Ltd

Chart & Performance

D1W1MN
XJPX:4571 chart
P/E
—
P/S
70.86
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.75%
Rev. gr., 5y
-22.88%
Revenues
136m
-32.98%
262,718,000353,648,000117,820,00084,337,000346,344,000373,778,000472,197,000675,801,000243,344,000218,694,000259,097,000496,732,000552,973,000313,264,000264,032,000202,189,000135,508,000
Net income
-780m
L-40.50%
-494,032,000-524,480,000-494,790,000-555,178,000-398,003,000-484,446,000-1,113,687,000-207,156,000-2,537,148,000-2,676,049,000-5,416,808,000-1,808,510,000-2,009,676,000-2,835,793,000-1,881,678,000-1,310,976,000-780,002,000
CFO
-585m
L-46.18%
-588,172,000-456,620,000-451,997,000-579,113,000-293,705,000-635,329,000-1,086,613,000-1,120,686,000-1,971,089,000-2,525,557,000-4,927,585,000-2,037,259,000-1,138,665,000-1,247,432,000-1,752,992,000-1,087,051,000-585,081,000

Profile

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's product pipeline includes VB-111 non-proliferative adenovirus vector, which is in phase III clinical trials for the treatment of ovarian cancer, as well as in phase II clinical trials for treatment of rGBM and colorectal cancer; ENT103 Otolaryngology product that is in phase III clinical trials for the treatment of otitis media; NC-6004 Cisplatin micelle, which is in phase II clinical trials for the treatment of head and neck cancer; NC-6300 Epirubicin micelle that is in phase I clinical trials for the treatment of hemangiosarcoma; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma and RUNX1 (mRNA) for osteoarthritis of the knee that are in preclinical stage. The company was founded in 1996 and is headquartered in Tokyo, Japan.
URL
https://www.nanocarrier.co.jp/
IPO date
Mar 05, 2008
Employees
17
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
135,508
-32.98%
202,189
-23.42%
264,032
-15.72%
Cost of revenue
671,954
1,162,590
1,965,039
Unusual Expense (Income)
NOPBT
(536,446)
(960,401)
(1,701,007)
NOPBT Margin
Operating Taxes
2,490
2,490
2,621
Tax Rate
NOPAT
(538,936)
(962,891)
(1,703,628)
Net income
(780,002)
-40.50%
(1,310,976)
-30.33%
(1,881,678)
-33.65%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,728
(936)
BB yield
-0.03%
0.01%
Debt
Debt current
(54,115)
Long-term debt
1,108,916
1,108,916
1,150,000
Deferred revenue
25,997
25,808
Other long-term liabilities
54,436
22,447
24,066
Net debt
(3,526,539)
(4,449,787)
(3,046,515)
Cash flow
Cash from operating activities
(585,081)
(1,087,051)
(1,752,992)
CAPEX
(6,215)
Cash from investing activities
793,007
1,207,913
(244,133)
Cash from financing activities
3,728
32,199
1,145,835
FCF
(538,936)
(956,365)
(1,508,389)
Balance
Cash
4,277,635
4,443,703
5,945,000
Long term investments
357,820
1,115,000
(1,802,600)
Excess cash
4,628,680
5,548,594
4,129,198
Stockholders' equity
(2,101,490)
(1,246,123)
(4,369,640)
Invested Capital
6,686,231
6,651,380
11,044,139
ROIC
ROCE
EV
Common stock shares outstanding
70,295
70,092
69,957
Price
185.00
-22.92%
240.00
-6.98%
258.00
-15.96%
Market cap
13,004,622
-22.69%
16,822,075
-6.80%
18,049,034
-13.90%
EV
9,478,083
12,372,288
15,016,059
EBITDA
(535,342)
(960,265)
(1,697,817)
EV/EBITDA
Interest
10,123
5,671
5,754
Interest/NOPBT